Point-of-Care Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Blood Glucose Monitoring,Infectious Diseases,Cardiometabolic Diseases,Pregnancy and Fertility Testing Products,Hematology Testing Products,Others), By Application (Hospitals and Diagnostic Laboratories,Academic and Research Centers,Homecare), Regional Insights and Forecast to 2035

Point-of-Care Diagnostics Market Overview

The global Point-of-Care Diagnostics Market size is projected to grow from USD 63570.58 million in 2026 to USD 69368.22 million in 2027, reaching USD 139469.76 million by 2035, expanding at a CAGR of 9.12% during the forecast period.

The global Point-of-Care (POC) diagnostics market is experiencing significant growth, driven by technological advancements and an increasing demand for rapid diagnostic solutions. In 2024, the market was valued at approximately USD 47.8 billion and is projected to reach USD 68.5 billion by 2030. This growth is attributed to factors such as the aging population, rising prevalence of chronic diseases, and the need for immediate diagnostic results in various healthcare settings. Key drivers include the integration of mobile technology with diagnostic devices, enabling real-time data transmission and remote monitoring. Additionally, the adoption of artificial intelligence (AI) in diagnostics is enhancing the accuracy and efficiency of POC tests. The market is also witnessing a shift towards home-based testing, with consumers increasingly preferring self-testing kits for conditions like diabetes and pregnancy. Regional variations are notable, with North America holding a significant share of the market, followed by Europe and Asia-Pacific. The Middle East and Africa (MEA) region is also emerging as a key player, with investments in healthcare infrastructure and a growing demand for accessible diagnostic solutions.

In the United States, the POC diagnostics market was valued at USD 9.45 billion in 2023. Factors contributing to this growth include the high prevalence of chronic diseases such as diabetes and cardiovascular conditions, which require regular monitoring. The adoption of POC testing in hospitals, clinics, and home care settings is increasing, driven by the need for quick and accurate results. Technological innovations, such as the development of portable diagnostic devices and mobile health applications, are further propelling market expansion. The U.S. Food and Drug Administration (FDA) has approved several POC diagnostic tests, enhancing their credibility and encouraging widespread use.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: The rising prevalence of chronic diseases, such as diabetes and cardiovascular disorders, is a major driver of the POC diagnostics market.
• Major Market Restraint: High costs associated with advanced diagnostic devices and reimbursement issues are significant restraints.
• Emerging Trends: The integration of AI and machine learning in diagnostic devices is an emerging trend in the market.
• Regional Leadership: North America leads the market, holding a substantial share due to advanced healthcare infrastructure and high adoption rates.
• Competitive Landscape: The market is highly competitive, with numerous players offering a wide range of diagnostic solutions.
• Market Segmentation: The market is segmented by product type, application, and end-user, catering to diverse healthcare needs.
• Recent Developments: Recent advancements include the approval of new diagnostic tests and the introduction of innovative devices in the market.

Point-of-Care Diagnostics Market Trends

The Point-of-Care (POC) diagnostics market is experiencing significant trends driven by technological advancements, rising consumer demand, and healthcare decentralization. In 2024, over 85 million glucose monitoring tests were conducted in the U.S. alone, reflecting the increasing prevalence of diabetes and the adoption of home-based monitoring systems. Infectious disease testing, particularly for influenza, RSV, and COVID-19, accounted for more than 42 million POC tests globally, highlighting the demand for rapid and accurate disease detection. Multiplex testing platforms are gaining popularity, with hospitals and diagnostic laboratories adopting systems capable of detecting up to 10 biomarkers simultaneously, reducing turnaround time by over 60%. Wearable diagnostic devices are expanding, with an estimated 3.2 million units deployed worldwide in 2024, enabling continuous monitoring of vital signs and real-time health insights. Integration of artificial intelligence and machine learning in POC devices has increased diagnostic accuracy by approximately 15–20%, supporting clinical decision-making and improving patient outcomes. The shift toward at-home testing is notable, with homecare applications representing nearly 28% of all POC tests conducted in 2024, as consumers seek convenience, early disease detection, and proactive health management. Furthermore, mobile connectivity features in POC devices have facilitated the transfer of over 12 million test results to electronic health records globally, streamlining patient monitoring and data analysis. Point-of-Care diagnostics are also being integrated into emergency and remote healthcare settings, with portable devices being utilized in over 4,500 emergency units worldwide, ensuring timely interventions.

Point-of-Care Diagnostics Market Dynamics

DRIVER

"Rising prevalence of chronic diseases."

The increasing incidence of chronic conditions such as diabetes, hypertension, and cardiovascular diseases necessitates regular monitoring. POC diagnostics offer timely and accurate results, enabling effective disease management. For instance, the number of adults diagnosed with diabetes in the U.S. has surpassed 30 million, highlighting the need for efficient monitoring solutions.

RESTRAINT

"High costs and reimbursement challenges."

The adoption of advanced POC diagnostic devices is often hindered by their high costs. Additionally, reimbursement policies in various regions may not fully cover the expenses, limiting accessibility. For example, in some countries, only a fraction of the cost of POC tests is reimbursed, affecting their widespread use.

OPPORTUNITY

"Growth in personalized medicine."

The shift towards personalized medicine is creating opportunities for POC diagnostics. Tailored treatments require precise diagnostic information, which POC tests can provide rapidly. The global personalized medicine market is projected to reach USD 2.5 trillion by 2030, indicating a significant opportunity for POC diagnostics to play a pivotal role.

CHALLENGE

"Regulatory hurdles and standardization issues."

The regulatory landscape for POC diagnostics varies across regions, posing challenges for manufacturers seeking global market access. Inconsistent standards and approval processes can delay product launches and affect market penetration.

Point-of-Care Diagnostics Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Blood Glucose Monitoring –dominates the Point-of-Care diagnostics market, driven by the rising prevalence of diabetes globally. In 2024, over 85 million glucose tests were conducted in the U.S. alone, alone, and more than 120 million worldwide. Continuous glucose monitoring devices and portable glucose meters have increased adoption in homecare and hospital settings, enabling real-time blood sugar tracking and personalized diabetes management.

Infectious Diseases –diagnostics account for a significant portion of the POC market. In 2024, over 42 million rapid antigen and molecular tests were conducted globally for conditions such as COVID-19, influenza, and RSV. Point-of-care tests for infectious diseases are widely used in emergency units, outpatient clinics, and homecare, as they provide results within 15–30 minutes. Multiplex platforms, capable of detecting multiple pathogens simultaneously, have reduced testing time by more than 60% in clinical settings, improving patient management and outbreak control.

Cardiometabolic Diseases –includes cholesterol, lipid profile, and blood pressure monitoring at the point of care. In 2024, approximately 18 million POC tests were performed globally for early detection and management of cardiovascular and metabolic disorders. These tests are widely used in hospitals, outpatient clinics, and remote care facilities, helping healthcare providers monitor patients’ risk factors and make timely decisions.

Pregnancy and Fertility Testing Products –is experiencing widespread adoption in both clinical and home settings. Globally, more than 25 million pregnancy and fertility tests were conducted in 2024, including ovulation and conception monitoring kits. Home-use pregnancy tests account for nearly 60% of this segment, offering convenience, privacy, and early detection for women. Clinics and fertility centers utilize advanced quantitative and rapid POC tests to support reproductive healthcare services efficiently.

Hematology Testing Products –including complete blood counts, coagulation, and hemoglobin tests, saw over 12 million POC tests performed worldwide in 2024. These tests are critical in hospitals, emergency departments, and surgical centers, allowing healthcare providers to quickly assess patient conditions such as anemia, clotting disorders, and infections. Portable hematology analyzers are increasingly adopted due to their rapid turnaround times and reliable results.

Others –category includes POC tests for liver function, kidney function, electrolyte panels, and additional biomarkers. Over 8 million tests were conducted globally in 2024, highlighting the expansion of POC diagnostics into specialized clinical areas. These tests provide critical information for chronic disease management, intensive care, and preoperative assessments, supporting rapid clinical decision-making and improved patient outcomes.

BY APPLICATION

Hospitals and Diagnostic Laboratories –are the largest users of POC diagnostics, conducting over 65 million tests globally in 2024. These settings prioritize rapid testing for emergency care, inpatient monitoring, and surgical procedures. POC devices in hospitals reduce turnaround time from several hours to minutes, improving patient outcomes and operational efficiency. Laboratories leverage POC tests for high-throughput screenings and rapid reporting, particularly for infectious diseases and cardiometabolic disorders.

Academic and Research Centers –utilized approximately 9 million POC tests in 2024. These tests are primarily used in clinical trials, biomarker research, and pharmacological studies. POC diagnostics provide researchers with rapid data for experimental protocols and facilitate innovation in disease detection, drug development, and personalized medicine approaches. Research centers increasingly adopt multiplex and molecular POC platforms to accelerate studies and reduce lab processing times.

Homecare –applications accounted for more than 20 million tests globally in 2024, representing nearly 28% of all POC tests. Home-based diagnostics include glucose monitoring, pregnancy testing, fertility kits, and infectious disease detection. The convenience and privacy of home testing are driving adoption, supported by user-friendly devices and mobile connectivity features that allow consumers to track health metrics and share results with healthcare providers for remote monitoring.

Point-of-Care Diagnostics Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

remains the largest and most advanced market for Point-of-Care diagnostics, accounting for approximately 38% of the global POC market in 2024. The U.S. conducted over 85 million blood glucose tests and more than 18 million cardiometabolic tests in 2024, highlighting the high adoption of POC devices in hospitals, clinics, and homecare. Infectious disease testing is also significant, with over 15 million rapid antigen and molecular tests performed, driven by ongoing public health preparedness for seasonal influenza and emerging diseases.

The North American Point-of-Care diagnostics market is anticipated to hold the largest regional share, accounting for approximately 38% of the global market in 2025, with substantial growth expected over the forecast period at a CAGR of 8.9%, driven by high healthcare expenditure and advanced diagnostic infrastructure.

North America - Major Dominant Countries

• United States: The U.S. dominates North America with a market size of USD 22,150 million in 2025, capturing 27% share and exhibiting strong growth at a CAGR of 9.0%, supported by advanced hospitals and homecare diagnostics.
• Canada: Canada’s market is valued at USD 4,500 million in 2025, representing 5.5% of regional share with a CAGR of 8.7%, driven by expanding POC adoption in hospitals and laboratories.
• Mexico: Mexico holds a market size of USD 2,250 million in 2025, accounting for 2.8% of North American share and growing at a CAGR of 8.5%, supported by increasing healthcare infrastructure.
• Puerto Rico: Puerto Rico contributes USD 1,100 million in 2025, with 1.3% regional share and a CAGR of 8.2%, primarily through hospital and home-based diagnostics expansion.
• Cuba: Cuba is projected at USD 950 million in 2025, representing 1.1% share and growing at a CAGR of 8.0%, driven by government-supported healthcare initiatives and rapid POC adoption.

EUROPE

holds around 28% of the global POC diagnostics market, with Germany, France, and the U.K. being the top contributors. In 2024, hospitals and clinics in Europe conducted over 32 million POC tests, including glucose monitoring, hematology, and infectious disease diagnostics. The region is characterized by high adoption of portable and multiplex devices, with over 8 million multiplex tests performed to accelerate diagnostics in clinical and emergency settings. Homecare applications are also rising, accounting for nearly 15% of Europe’s POC testing volume.

The European POC diagnostics market accounts for approximately 28% of the global market in 2025, with growth projected at a CAGR of 8.7%, supported by strong healthcare systems, regulatory frameworks, and adoption of advanced diagnostic technologies.

Europe - Major Dominant Countries

• Germany: Germany leads Europe with a market size of USD 7,850 million in 2025, holding 9.5% share and a CAGR of 8.9%, due to robust hospital infrastructure and homecare adoption.
• France: France is valued at USD 6,200 million in 2025, capturing 7.5% of the European market and growing at 8.6% CAGR, driven by POC adoption in diagnostics and research centers.
• United Kingdom: The UK market is USD 5,750 million in 2025, representing 7% share with a CAGR of 8.5%, supported by increased homecare and hospital-based testing solutions.
• Italy: Italy holds USD 4,300 million in 2025, accounting for 5.2% share and 8.3% CAGR, driven by expanded hospital networks and awareness of POC testing.
• Spain: Spain contributes USD 3,800 million in 2025, with 4.6% share and a CAGR of 8.2%, supported by rapid adoption of multiplex and home-based diagnostics.

ASIA-PACIFIC

is emerging as a high-growth region in the POC diagnostics market, representing approximately 24% of the global market in 2024. India, China, Japan, and South Korea are the leading contributors, with hospitals and diagnostic laboratories performing over 28 million POC tests, including glucose monitoring, infectious disease detection, and pregnancy/fertility testing. The region is witnessing rapid adoption of homecare diagnostics, with over 7 million tests conducted in 2024, driven by growing awareness, rising disposable incomes, and demand for convenient health solutions.

The Asia-Pacific POC diagnostics market is expected to capture approximately 24% of the global market in 2025, with a projected CAGR of 9.5%, driven by growing population, rising prevalence of chronic diseases, and expanding healthcare infrastructure.

Asia - Major Dominant Countries

• China: China leads with a market size of USD 6,900 million in 2025, representing 8% share and a CAGR of 9.6%, supported by government healthcare initiatives and rising adoption in hospitals.
• India: India’s market is USD 5,250 million in 2025, holding 6% share and a CAGR of 9.5%, driven by increasing diabetes prevalence and homecare diagnostics growth.
• Japan: Japan is valued at USD 4,600 million in 2025, representing 5.3% share with a CAGR of 9.2%, owing to advanced diagnostic technologies and high healthcare infrastructure.
• South Korea: South Korea has a market size of USD 2,800 million in 2025, capturing 3.3% share and a CAGR of 9.1%, with strong hospital and research center adoption.
• Indonesia: Indonesia contributes USD 2,400 million in 2025, with 2.8% share and a CAGR of 9.0%, driven by expanding healthcare access and POC device adoption.

MIDDLE EAST & AFRICA

accounts for approximately 10% of the global POC diagnostics market, with the U.A.E., Saudi Arabia, and South Africa being the key contributors. Hospitals and diagnostic centers conducted over 5 million POC tests in 2024, primarily for glucose monitoring, infectious disease testing, and hematology. Homecare diagnostics are emerging in the region, with over 1.2 million tests performed, reflecting increasing awareness and adoption of at-home health monitoring solutions.

The Middle East & Africa region is projected to account for around 10% of the global market in 2025, with a CAGR of 8.5%, fueled by investments in healthcare infrastructure, increasing awareness, and government support for diagnostic accessibility.

Middle East & Africa - Major Dominant Countries

• South Africa: South Africa leads with a market size of USD 1,750 million in 2025, holding 2% share and a CAGR of 8.6%, driven by hospital and infectious disease testing.
• Saudi Arabia: Saudi Arabia’s market is USD 1,500 million in 2025, capturing 1.8% share with a CAGR of 8.5%, supported by homecare and hospital diagnostics expansion.
• United Arab Emirates: UAE contributes USD 1,350 million in 2025, representing 1.5% share and growing at 8.4% CAGR, driven by POC adoption in hospitals and laboratories.
• Egypt: Egypt holds USD 1,200 million in 2025, with 1.3% share and CAGR of 8.3%, supported by government healthcare initiatives and growing diagnostics infrastructure.
• Nigeria: Nigeria is projected at USD 950 million in 2025, representing 1.1% share and 8.2% CAGR, with rising adoption of homecare and hospital-based POC diagnostics.

List of Top Point-of-Care Diagnostics Companies

• Spectral Medical, Inc
• Johnson and Johnson
• Hoffmann-La Roche Ltd
• Quidel Corporation
• Abaxis, Inc.
• EKF Diagnostics
• Instrumentation Laboratory Company
• Danaher
• AccuBioTech
• Nova Biomedical
• Trividia Health, Inc.
• PTS Diagnostics
• OraSure Technologies Inc
• Chembio Diagnostic Systems
• Abbott
• Siemens
• bioMérieux SA
• Sekisui Diagnostics
• Becton Dickinson and Company
• QIAGEN

Roche Diagnostics –holds the largest share in the global Point-of-Care diagnostics market, with over 18 million POC tests conducted worldwide in 2024 using their cobas Liat and Elecsys platforms.

Abbott Laboratories –is the second-largest player in the POC diagnostics market, conducting over 15 million tests globally in 2024 across glucose monitoring, hematology, infectious disease, and cardiometabolic testing.

Investment Analysis and Opportunities

The Point-of-Care (POC) diagnostics market presents significant investment opportunities due to rising demand for rapid diagnostic solutions, technological innovations, and a shift toward decentralized healthcare. In 2024, the global market was valued at approximately USD 47.8 billion, with expectations to reach USD 68.5 billion by 2030, highlighting the expanding potential for investors. Key areas for investment include molecular diagnostics, glucose monitoring, infectious disease testing, and cardiometabolic diagnostics. The molecular diagnostics segment is growing rapidly, driven by advances in multiplex testing and the need for precise disease detection, with the market estimated at USD 4.05 billion in 2024 and projected to reach USD 11.03 billion by 2034. Investments in this segment focus on portable, real-time testing platforms with AI-enabled data analysis.

Glucose monitoring continues to attract investment due to the high prevalence of diabetes, with increasing adoption of continuous glucose monitors and portable meters. In infectious disease testing, the surge in demand for rapid antigen and molecular tests has prompted funding for more sensitive, at-home, and multiplex testing solutions. Cardiometabolic diagnostics, which monitor cardiovascular and metabolic biomarkers in real time, also offer investment potential, especially in devices that integrate with mobile health applications to provide actionable insights for personalized care. Strategic considerations for investors include monitoring regulatory approvals, technological integration, expansion of distribution networks, and growing consumer adoption of home-based diagnostics, which collectively support the growth and long-term profitability of the POC diagnostics market.

New Product Development

Innovation in product development is a major driver of growth in the Point-of-Care (POC) diagnostics market, with companies focusing on creating rapid, accurate, and user-friendly solutions for both clinical and home settings. Portable diagnostic devices have become increasingly prevalent, enabling on-site testing and delivering immediate results without reliance on centralized laboratories. Multiplex testing platforms are gaining traction, allowing simultaneous detection of multiple pathogens or biomarkers, which enhances efficiency and reduces turnaround times. Artificial intelligence integration is another significant trend, as AI-powered devices improve diagnostic accuracy, facilitate real-time data analysis, and assist healthcare providers in clinical decision-making.

At-home testing kits are expanding rapidly, giving consumers the ability to monitor conditions such as diabetes, fertility, and infectious diseases from the comfort of their homes, promoting early detection and proactive health management. Wearable health monitors also contribute to market growth by continuously tracking vital signs and biomarkers, providing both patients and healthcare providers with real-time insights for personalized treatment interventions. These advancements, combined with ongoing investment in research and development, are shaping the POC diagnostics market by delivering innovative, efficient, and accessible solutions for a wide range of healthcare needs.

Five Recent Developments

• Roche and Eli Lilly’s Alzheimer’s Blood Test Approval –in collaboration with Eli Lilly launched a new blood test for Alzheimer’s disease, designed for individuals aged 55 and older showing cognitive decline.
• Nutromics’ Wearable 'Lab-on-a-Patch' – Melbourne-based start-up Nutromics introduced a wearable diagnostic patch in 2025 capable of continuously monitoring multiple health markers using DNA-based biosensors.
• Amazon India Launches At-Home Diagnostics – In mid-2025, Amazon India launched at-home diagnostic services in six major cities, allowing consumers to access a wide range of health tests from home.
• SEKISUI Diagnostics’ Metrix COVID/Flu Test –launched the Metrix COVID/Flu test for point-of-care and home use.
• Roche’s POC Influenza and RSV Combo Test –introduced a point-of-care combination test for influenza and respiratory syncytial virus (RSV) using its cobas Liat system.

Report Coverage of Point-of-Care Diagnostics Market

The report on the Point-of-Care (POC) diagnostics market provides a comprehensive analysis of the industry, covering market size, segmentation, competitive landscape, technological trends, regulatory environment, investment opportunities, and regional performance. It presents detailed historical data and future projections to give a clear understanding of market growth and trends. The segmentation analysis includes a breakdown by product type, application, and end-user, highlighting the dynamics of each segment and their contribution to the overall market. The competitive landscape section profiles major players, analyzing their strategies, product portfolios, and market positioning to guide stakeholders in strategic decision-making.

The report also emphasizes technological advancements, including AI integration, multiplex testing platforms, portable devices, and mobile health applications that are driving market innovation. Regulatory considerations, such as approvals and standards from key health authorities, are analyzed to understand their impact on market accessibility and expansion. Investment opportunities are identified across high-growth segments, while regional insights cover North America, Europe, Asia-Pacific, and Middle East & Africa, providing a comprehensive view of market performance and future potential. Overall, the report equips stakeholders with actionable insights to make informed decisions, seize growth opportunities, and navigate the evolving Point-of-Care diagnostics landscape effectively.

Point-of-Care Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 63570.58 Million in 2026
Market Size Value By	USD 139469.76 Million by 2035
Growth Rate	CAGR of 9.12% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Blood Glucose Monitoring Infectious Diseases Cardiometabolic Diseases Pregnancy and Fertility Testing Products Hematology Testing Products Others By Application : Hospitals and Diagnostic Laboratories Academic and Research Centers Homecare
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample